May 27, 2024
In the Medical Xpress, “Co-author Professor Ramanan Laxminarayan, President of the One Health Trust and Senior Research Scholar at Princeton University, says, ‘Reducing the impact of AMR through pharmaceuticals is not simply a matter of developing new antibiotics. Unless access and affordability are guaranteed, the vast number of deaths from resistant bacterial infections will continue unabated. Reducing the cost of drug development would help keep antibiotics affordable, as shown by the public-private partnerships for medications to treat malaria and neglected tropical diseases. It’s time for similar tactics in antibiotic development.'”
Read more here.
